NCT06032728View on ClinicalTrials.gov

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

NANot yet recruitingINTERVENTIONAL
Enrollment

488

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 1, 2033

Study Completion Date

October 1, 2033

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Sunitinib

The investigators randomly assign multimodal recurrence scoring system defined high risk patients of stage III ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation

All Listed Sponsors
lead

First Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT06032728 - Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment | Biotech Hunter | Biotech Hunter